Osilodrostat, a dual CYP11B1 and CYP11B2 inhibitor, has shown efficacy in patients with Cushing’s syndrome, particularly those with coexisting hypertension and metabolic disturbances. The gene discussed is CYP11B2; the disease is Hypertension.